Eli Lilly Net Change in Property, Plant, and Equipment 2010-2024 | LLY
Eli Lilly annual/quarterly net change in property, plant, and equipment history and growth rate from 2010 to 2024. Net change in property, plant, and equipment can be defined as the overall change in capital expenditures and sales of plant, property and equipment. This field is used if a company does not report separately sales and purchases of plant, property and equipment or is calculated as the sum of purchases and sales of PP&E
- Eli Lilly net change in property, plant, and equipment for the quarter ending December 31, 2024 was $-5.058B, a 46.7% increase year-over-year.
- Eli Lilly net change in property, plant, and equipment for the twelve months ending December 31, 2024 was $-11.817B, a 49.59% increase year-over-year.
- Eli Lilly annual net change in property, plant, and equipment for 2024 was $-5.058B, a 46.7% increase from 2023.
- Eli Lilly annual net change in property, plant, and equipment for 2023 was $-3.448B, a 85.92% increase from 2022.
- Eli Lilly annual net change in property, plant, and equipment for 2022 was $-1.854B, a 41.57% increase from 2021.
Eli Lilly Annual Net Change in Property, Plant, and Equipment
(Millions of US $) |
| 2024 |
$-5,058 |
| 2023 |
$-3,448 |
| 2022 |
$-1,854 |
| 2021 |
$-1,310 |
| 2020 |
$-1,388 |
| 2019 |
$-1,034 |
| 2018 |
$-1,211 |
| 2017 |
$-1,077 |
| 2016 |
$-964 |
| 2015 |
$-974 |
| 2014 |
$-1,147 |
| 2013 |
$-833 |
| 2012 |
$-883 |
| 2011 |
$-647 |
| 2010 |
$-670 |
| 2009 |
$-747 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$796.425B |
$45.043B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
